IMA: Held by 5 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›ImageneBio, Inc. (IMA)

ImageneBio, Inc.

IMA

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions.

BiotechnologyCEO: Kristin YaremaIPO: 1998Website ↗

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.5/10

5 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 5 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

5 fund convergence

OrbiMed AdvisorsHeld 7Q ↓

RTW InvestmentsHeld 2Q

BVF PartnersHeld 2Q

Deep Track Capital

Boxer CapitalNew

Position history (shares)

OrbiMed Advisors

RTW Investments

BVF Partners

AI Signal

SIGNAL NOTE: IMA

BVF Partners' $6.5M initiating position joins four other specialist biotech funds (RTW, OrbiMed, Deep Track, Boxer), signaling high-conviction convergence around ImageneBio's pipeline. This level of specialist fund clustering typically precedes inflection points, though near-term catalysts and cash runway require verification given IMA's early-stage status.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Aug 14, 2025

$13.1M

1 fund

Nov 14, 2025

$32.0M

4 funds

Feb 13, 2026

0 funds

Feb 17, 2026

$30.6M

3 funds

-43% total institutional value over 13 quarters

Short Interest

Short Shares

387K

Change

+2.4%

Days to Cover

0.6

Settlement

Apr 15, 2026

Short interest over 5 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13D/AOrbiMed Advisors13.1%Apr 29, 2026

SC 13G/ADeep Track Capital0.0%Feb 13, 2026

SC 13GDeep Track Capital7.9%Aug 4, 2025

SC 13D/AOrbiMed Advisors6.9%Jul 30, 2025

SC 13D/AOrbiMed Advisors16.7%Jun 18, 2025

Position Details

OrbiMed AdvisorsFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

18 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

EXAS1 fund CTMX1 fund IRON1 fund CRVS1 fund QTTB1 fund RLMD1 fund ADCT1 fund ACET1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer